Addex Therapeutics LTD (ADXN) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

ADXN ranks #16947 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

2 institutions disclose a position in ADXN, but none treat it as a major bet — even UBS Group AG, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

ADXN reported a net loss of $6.7M in its latest fiscal year.

• Not yet profitable — net loss of $6.7M in the latest fiscal year
• Revenue declined 92.6% year over year
• Net income declined year over year, from $7.1M to -$6.7M
• Operating cash flow was negative, using $2.2M in cash
• Current ratio of 1.40x — below the conventional 1.5x liquidity buffer
• Liabilities run 1.34x equity — within a conventional range